Natco Pharma surges as its distribution partner gets tentative approval for Ibrutinib tablets

12 Apr 2021 Evaluate

Natco Pharma is currently trading at Rs. 941.20, up by 19.45 points or 2.11% from its previous closing of Rs. 921.75 on the BSE.

The scrip opened at Rs. 950.00 and has touched a high and low of Rs. 950.00 and Rs. 906.45 respectively. So far 18174 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 556.50 on 15-May-2020.

Last one week high and low of the scrip stood at Rs. 950.00 and Rs. 826.60 respectively. The current market cap of the company is Rs. 17053.15 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 32.49% and 18.65% respectively.

Natco Pharma’s marketing and distribution partner -- Alvogen Pine Brook LLC has received tentative approval for Abbreviated New Drug Application (ANDA) Ibrutinib Tablets 560mg, 420mg, 280mg and 140mg strengths (generic for Imbruvica), from the U.S. Food and Drug Administration (USFDA).

As per industry sales data, Imbruvica (Tablet and Capsule dosage forms) had generated annual sales of $3.7 billion during the twelve months period ending December 2020 in the US market, of this, all the strengths of Imbruvica Tablets alone generated sales of $3.0 billion during the same period.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

954.45 -17.55 (-1.81%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.